



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 7596

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

10 August 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Nivolumab.

You asked:

Q1. In the last 3 months, how many patients have been initiated on the following agents for the treatment of melanoma?*

- a. Nivolumab (monotherapy)*
- b. Nivolumab AND Ipilimumab (combination)*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q2. In the last 3 months, how many patients have been initiated on the following agents for the treatment of Renal Cell Carcinoma?*

- a. Nivolumab (monotherapy)*
- b. Nivolumab + Ipilimumab*
- c. Nivolumab + Cabozantinib*
- d. Avelumab + Axitinib*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q3. In the past 3 months, how many patients have been initiated on the following agents for the treatment of upper gastrointestinal cancer (oesophageal cancer, gastric cancer and gastro-oesophageal junction cancer)?*

- a. Nivolumab*
- b. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q4. Does your trust participate in any clinical trials for the treatment of Melanoma? If so, please provide the name of each active trial, and the number of patients taking part.

Q5. Does your trust participate in any clinical trials for the treatment of Renal Cell Carcinoma? If so, please provide the name of each active trial, and the number of patients taking part.

Trust response:

Q1.

a. 0

b. 4

Q2.

a. 1

b. 1

c. 0

d. 1

Q3.

a. 4

b. 1

Q4. Dante is the trial name and we have two patients on study.

Q5. No current studies open on site at the moment.